Genetic testing giant 23andMe cuts 40% of workforce, discontinues therapeutics division
NEW YORK — 23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs. The latest restructuring efforts were announced by 23andMe ...
23andMe Lays Off 40% of Its Workforce as Company Spirals
The genetic testing company 23andMe announced it was laying off more than 200 employees, or roughly 40% of its entire workforce, according to a press release Monday. The move is part of a restructuring that will see the company also halt the development of its therapeutics division which had been working on various potential medical treatments.
Concerns about 23andMe's business prospects is raising questions about the genetic testing company's customer data.
The financial struggles of genetic testing and ancestry company 23andMe are raising questions about the security of customers ...
23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...
23andMe, a popular South San Francisco-based genetic testing company, is laying off 40% of its workers after struggling with ...
The company said it is evaluating strategic alternatives, including licensing agreements and asset sales, for its therapies ...
Me is to cut 200 jobs in the wake of declining revenues. This company expects a proposed retructuring, affecting 40% of its ...
Genetic-testing lab 23andMe plans to cut its workforce by 40% and end its therapeutics program in an effort to cut costs, the ...
On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...
More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs ...
o. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered ...
DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback